➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Johnson and Johnson
Harvard Business School
Merck
McKesson

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

ALLOPURINOL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Allopurinol patents expire, and what generic alternatives are available?

Allopurinol is a drug marketed by Accord Hlthcare, Apotex Inc, Fosun Pharma, Indoco, Ipca Labs Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Unichem Labs Ltd, Vintage Pharms, Watson Labs, Zydus Pharms, and West-ward Pharms Int. and is included in twenty-six NDAs.

The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Allopurinol

A generic version of ALLOPURINOL was approved as allopurinol sodium by WEST-WARD PHARMS INT on August 26th, 2004.

  Start Trial

Drug patent expirations by year for ALLOPURINOL
Drug Prices for ALLOPURINOL

See drug prices for ALLOPURINOL

Drug Sales Revenue Trends for ALLOPURINOL

See drug sales revenues for ALLOPURINOL

Recent Clinical Trials for ALLOPURINOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 2/Phase 3
InCor Heart InstitutePhase 2/Phase 3
Ministry of Health, BrazilPhase 2/Phase 3

See all ALLOPURINOL clinical trials

Pharmacology for ALLOPURINOL
Medical Subject Heading (MeSH) Categories for ALLOPURINOL

US Patents and Regulatory Information for ALLOPURINOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs ALLOPURINOL allopurinol TABLET;ORAL 018785-001 Sep 28, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Unichem Labs Ltd ALLOPURINOL allopurinol TABLET;ORAL 211820-002 Mar 12, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs ALLOPURINOL allopurinol TABLET;ORAL 018832-002 Sep 28, 1984 AB RX No No   Start Trial   Start Trial   Start Trial
Vintage Pharms ALLOPURINOL allopurinol TABLET;ORAL 075798-001 Jun 27, 2003 AB RX No No   Start Trial   Start Trial   Start Trial
Accord Hlthcare ALLOPURINOL allopurinol TABLET;ORAL 203154-001 May 6, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Dow
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.